Schering-Plough

Ipsen appoints Dr. Alexandre Lebeaut as EVP, R&D, and chief scientific officer

Tuesday, April 18, 2017

Ipsen announced the appointment of Dr. Alexandre Lebeaut as executive vice president, R&D, and chief scientific officer, effective immediately. Dr. Lebeaut will report directly to David Meek, CEO of Ipsen, and serve on the executive leadership team. Dr. Lebeaut joined Ipsen in 2013 as senior vice president, chief development officer, Global Drug Development and was appointed interim head of R&D in December 2016.

[Read More]

Bristol-Myers Squibb appoints three new independent directors

Tuesday, February 21, 2017

Bristol-Myers Squibb has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its board of directors, effective immediately. In connection with these appointments, the board will temporarily expand to 14 directors until the 2017 Annual Meeting, to be held on May 2, 2017. Only 11 directors will stand for election at the meeting. Bristol-Myers Squibb also announced that it has entered into an accelerated share repurchase (ASR) program to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock.

[Read More]

Foundation Medicine appoints Troy Cox CEO

Monday, January 9, 2017

Foundation Medicine has announced that, as part of the succession of its executive leadership, the board of directors has appointed Troy Cox, a highly regarded global biopharma leader, as chief executive officer to succeed Michael Pellini, M.D. Dr. Pellini, who has served as chief executive officer of the company since 2011, has been appointed chairman of the company’s board of directors. Alexis Borisy, founding chief executive officer and current chairman of the board for Foundation Medicine, will continue to serve on the board of directors. Cox will also join the board of directors. All of these changes will become effective by February 6, 2017.

[Read More]

PureTech, Siddhartha Mukherjee launch Vor BioPharma

Wednesday, May 11, 2016

PureTech Health has launched Vor BioPharma, an immuno-oncology company dedicated to developing a new class of targeted cell therapies. The company, which is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy, has licensed its core technology from the lab of Vor scientific co-founder, Siddhartha Mukherjee, M.D., Ph.D., assistant professor of Medicine at Columbia University and Pulitzer Prize-winning author of The Emperor of All Maladies: A Biography of Cancer.

[Read More]

Finding investigators and patients for faster trials

Friday, April 15, 2016

In the January issue of The CenterWatch Monthly, I wrote about using insurance claims and electronic health records (EHR) to understand patient availability for clinical trials. Combined, these sources can tell you if enough patients meet the criteria, enabling redesign and better planning.

[Read More]